Tarsus to Participate in Upcoming Investor Conferences
30 Janeiro 2025 - 7:00PM
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that
management will participate in fireside chats at two upcoming
investor conferences:
- The Guggenheim SMID Cap Biotech Conference on Thursday,
February 6th, at 6:00 a.m. PT / 9:00 a.m. ET
- The Oppenheimer 35th Annual Healthcare Life Sciences Conference
on Wednesday, February 12th, at 7:00 a.m. PT / 10:00 a.m. ET
A live webcast and additional information can be accessed on the
events section of the Tarsus website. The replay will be available
on the Tarsus website within 48 hours and will be archived for a
limited time.
About Tarsus Pharmaceuticals, Inc.Tarsus
Pharmaceuticals, Inc. applies proven science and new technology to
revolutionize treatment for patients, starting with eye care.
Tarsus is advancing its pipeline to address several diseases with
high unmet need across a range of therapeutic categories, including
eye care and infectious disease prevention. XDEMVY® (lotilaner
ophthalmic solution, 0.25%) is FDA approved in the United States
for the treatment of Demodex blepharitis. Tarsus is also developing
TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an
oral tablet for the potential prevention of Lyme disease.
Media Contact:Adrienne KempSr. Director,
Corporate Communications(949) 922-0801AKemp@tarsusrx.com
Investor Contact:David NakasoneHead of Investor
Relations(949) 620-3223DNakasone@tarsusrx.com
Tarsus Pharmaceuticals (NASDAQ:TARS)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025
Tarsus Pharmaceuticals (NASDAQ:TARS)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025
